We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

While uncertainty often casts a shadow on the Street, U.S. investors welcomed the presidential and congressional election results with a late-night surge that carried into this morning. The Dow Jones ...

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

By prioritising local production of essential pharmaceuticals, the government seeks not only to secure the healthcare needs ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK sales hampered by slump in demand for key vaccine - The drugmaker said sales of Arexvy fell sharply in the third quarter, ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...